SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : biotech firesales -- Ignore unavailable to you. Want to Upgrade?


To: tuck who wrote (3323)2/11/2016 2:15:36 PM
From: Pravda  Read Replies (1) | Respond to of 3661
 
HALO seems to be up on INCY's poor pancreatic cancer trial. (Horrible disease.)

Any thoughts?

Pravda



To: tuck who wrote (3323)4/6/2018 9:29:48 AM
From: tuck  Respond to of 3661
 
Incyte (INCY) of 20% from already depressed prices on failure of ECHO-301, a P3 study of the IDO/PD1 combo in melanoma. This is also taking NewLink (NLNK) down, even harder, because it has no other program outside of its even sketchier IDO effort: 40%.

Not a buying op in either, IMO.

Cheers, Tuck